scPharmaceuticals Inc
NASDAQ:SCPH

Watchlist Manager
scPharmaceuticals Inc Logo
scPharmaceuticals Inc
NASDAQ:SCPH
Watchlist
Price: 5.67 USD Market Closed
Market Cap: 304.4m USD

Operating Margin
scPharmaceuticals Inc

-159.2%
Current
-429%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-159.2%
=
Operating Profit
-79.6m
/
Revenue
50m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
scPharmaceuticals Inc
NASDAQ:SCPH
302.2m USD
-159%
US
Eli Lilly and Co
NYSE:LLY
985.1B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
491.6B USD
27%
CH
Roche Holding AG
SIX:ROG
259.3B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
209.2B GBP
24%
US
Merck & Co Inc
NYSE:MRK
267.2B USD
38%
CH
Novartis AG
SIX:NOVN
210.7B CHF
33%
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
143.1B USD
29%
No Stocks Found

scPharmaceuticals Inc
Glance View

Market Cap
302.2m USD
Industry
Pharmaceuticals

scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2017-11-17. The firm is focused on exploring, developing and commercializing products that expand and advance the outpatient care of acute conditions, including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for treatment of congestion in patients with heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization. Its area of focus is congestion in heart failure and outpatient parenteral antimicrobial therapy (OPAT). Its pipeline programs include FUROSCIX, scCeftriaxone and scCarbapenem. Its FUROSCIX On-Body Infusor is a drug-device combination product consisting of FUROSCIX. The firm's wholly owned subsidiary is scPharmaceuticals Securities Corporation.

SCPH Intrinsic Value
11.48 USD
Undervaluation 51%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-159.2%
=
Operating Profit
-79.6m
/
Revenue
50m
What is the Operating Margin of scPharmaceuticals Inc?

Based on scPharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -159.2%.

Back to Top